Lymphoma
2024 ASCO | Relma-cel Achieves a 4-Year OS Rate of 66.7% in Treating R/R LBCL, Making Lymphoma Cure Possible Over the past few decades, there have been significant advancements in the treatment of hematologic malignancies, particularly with CAR-T cell therapy. Recently, Relma-cel (relmacabtagene autoleucel) showcased promising new data at the 2024 American Society of Clinical Read More
## Chinese Medical Team: Sequential CD20 CAR-T Therapy Outperforms Salvage Chemotherapy for CD19 CAR-T Resistant B-Cell Lymphoma Patients In recent years, with the application of CD19 CAR-T in refractory/relapsed B-cell lymphoma, we have encountered patients for whom CD19 CAR-T therapy was ineffective or who relapsed shortly after initial success. While research continues to explore factors Read More
Approved by the U.S. Food and Drug Administration (FDA) on August 30, 2017, Kymriah represents a significant advancement in immunotherapy, offering hope to patients who have exhausted conventional treatments.